Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

A novel upstream enhancer of FOXP3, sensitive to methylation-induced silencing, exhibits dysregulated methylation in rheumatoid arthritis Treg cells.

Kennedy A, Schmidt EM, Cribbs AP, Penn H, Amjadi P, Syed K, Read JE, Green P, Gregory B, Brennan FM.

Eur J Immunol. 2014 Oct;44(10):2968-78. doi: 10.1002/eji.201444453. Epub 2014 Aug 18.

2.

Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway.

Cribbs AP, Kennedy A, Penn H, Read JE, Amjadi P, Green P, Syed K, Manka SW, Brennan FM, Gregory B, Williams RO.

Arthritis Rheumatol. 2014 Sep;66(9):2344-54. doi: 10.1002/art.38715.

3.

Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells.

Cribbs AP, Kennedy A, Gregory B, Brennan FM.

BMC Biotechnol. 2013 Nov 12;13:98. doi: 10.1186/1472-6750-13-98.

4.

Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures.

Schmidt EM, Davies M, Mistry P, Green P, Giddins G, Feldmann M, Stoop AA, Brennan FM.

Arthritis Rheum. 2013 Sep;65(9):2262-73. doi: 10.1002/art.38055.

5.

CXCR4 and vascular cell adhesion molecule 1 are key chemokine/adhesion receptors in the migration of cytokine-activated T cells.

Bryant J, Ahern DJ, Brennan FM.

Arthritis Rheum. 2012 Jul;64(7):2137-46. doi: 10.1002/art.34394.

6.

Production of TNF-α in macrophages activated by T cells, compared with lipopolysaccharide, uses distinct IL-10-dependent regulatory mechanism.

Agbanoma G, Li C, Ennis D, Palfreeman AC, Williams LM, Brennan FM.

J Immunol. 2012 Feb 1;188(3):1307-17. doi: 10.4049/jimmunol.1100625. Epub 2012 Jan 4.

7.

Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells.

Beavis PA, Gregory B, Green P, Cribbs AP, Kennedy A, Amjadi P, Palfreeman AC, Feldmann M, Brennan FM.

Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16717-22. doi: 10.1073/pnas.1112722108. Epub 2011 Sep 16.

8.

Blockade of NKG2D ameliorates disease in mice with collagen-induced arthritis: a potential pathogenic role in chronic inflammatory arthritis.

Andersson AK, Sumariwalla PF, McCann FE, Amjadi P, Chang C, McNamee K, Tornehave D, Haase C, Agersø H, Stennicke VW, Ahern D, Ursø B, Trowsdale J, Feldmann M, Brennan FM.

Arthritis Rheum. 2011 Sep;63(9):2617-29. doi: 10.1002/art.30460.

9.

The role of Natural Killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators?

Ahern DJ, Brennan FM.

Immunol Lett. 2011 May;136(2):115-21. doi: 10.1016/j.imlet.2010.11.001. Epub 2010 Nov 10. Review.

PMID:
21073898
10.

Activation of p38 mitogen-activated protein kinase is critical step for acquisition of effector function in cytokine-activated T cells, but acts as a negative regulator in T cells activated through the T-cell receptor.

Li C, Beavis P, Palfreeman AC, Amjadi P, Kennedy A, Brennan FM.

Immunology. 2011 Jan;132(1):104-10. doi: 10.1111/j.1365-2567.2010.03345.x. Epub 2010 Sep 28.

11.

Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood.

Page TH, Turner JJ, Brown AC, Timms EM, Inglis JJ, Brennan FM, Foxwell BM, Ray KP, Feldmann M.

J Immunol. 2010 Sep 15;185(6):3694-701. doi: 10.4049/jimmunol.1000906. Epub 2010 Aug 16.

12.

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

McCann FE, Palfreeman AC, Andrews M, Perocheau DP, Inglis JJ, Schafer P, Feldmann M, Williams RO, Brennan FM.

Arthritis Res Ther. 2010;12(3):R107. doi: 10.1186/ar3041. Epub 2010 Jun 2.

13.

Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis.

Hillyer P, Larché MJ, Bowman EP, McClanahan TK, de Waal Malefyt R, Schewitz LP, Giddins G, Feldmann M, Kastelein RA, Brennan FM.

Rheumatology (Oxford). 2009 Dec;48(12):1581-9. doi: 10.1093/rheumatology/kep293. Epub 2009 Oct 8.

14.

TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines.

Kuai J, Gregory B, Hill A, Pittman DD, Feldman JL, Brown T, Carito B, O'Toole M, Ramsey R, Adolfsson O, Shields KM, Dower K, Hall JP, Kurdi Y, Beech JT, Nanchahal J, Feldmann M, Foxwell BM, Brennan FM, Winkler DG, Lin LL.

Rheumatology (Oxford). 2009 Nov;48(11):1352-8. doi: 10.1093/rheumatology/kep235. Epub 2009 Aug 27.

PMID:
19713442
15.

Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures.

Sacre SM, Lo A, Gregory B, Simmonds RE, Williams L, Feldmann M, Brennan FM, Foxwell BM.

J Immunol. 2008 Dec 1;181(11):8002-9.

16.

Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717.

Sumariwalla PF, Palmer CD, Pickford LB, Feldmann M, Foxwell BM, Brennan FM.

Rheumatology (Oxford). 2009 Jan;48(1):32-8. doi: 10.1093/rheumatology/ken398. Epub 2008 Nov 16.

PMID:
19015145
17.

Evidence that cytokines play a role in rheumatoid arthritis.

Brennan FM, McInnes IB.

J Clin Invest. 2008 Nov;118(11):3537-45. doi: 10.1172/JCI36389. Review.

18.

Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis.

Andersson AK, Feldmann M, Brennan FM.

Scand J Immunol. 2008 Jul;68(1):103-11. doi: 10.1111/j.1365-3083.2008.02118.x. Epub 2008 May 9.

19.

Interleukin-10 regulates TNF-alpha-converting enzyme (TACE/ADAM-17) involving a TIMP-3 dependent and independent mechanism.

Brennan FM, Green P, Amjadi P, Robertshaw HJ, Alvarez-Iglesias M, Takata M.

Eur J Immunol. 2008 Apr;38(4):1106-17. doi: 10.1002/eji.200737821.

20.

Recent developments in the immunobiology of rheumatoid arthritis.

Andersson AK, Li C, Brennan FM.

Arthritis Res Ther. 2008;10(2):204. doi: 10.1186/ar2370. Epub 2008 Mar 14. Review.

21.

Resting CD4+ effector memory T cells are precursors of bystander-activated effectors: a surrogate model of rheumatoid arthritis synovial T-cell function.

Brennan FM, Smith NM, Owen S, Li C, Amjadi P, Green P, Andersson A, Palfreeman AC, Hillyer P, Foey A, Beech JT, Feldmann M.

Arthritis Res Ther. 2008;10(2):R36. doi: 10.1186/ar2390. Epub 2008 Mar 19.

22.

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katasikis P, Brennan FM, Bijl H, Ghrayeb J, Woody JN.

Arthritis Rheum. 2008 Feb;58(2 Suppl):S92-S101. doi: 10.1002/art.23362.

23.

Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue.

Sacre SM, Drexler SK, Andreakos E, Feldmann M, Brennan FM, Foxwell BM.

Ann Rheum Dis. 2007 Nov;66 Suppl 3:iii81-6. Review.

24.

Preparation of mononuclear cells from synovial tissue.

Beech JT, Brennan FM.

Methods Mol Med. 2007;135:105-19.

PMID:
17951655
25.

Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis.

Edwards CJ, Feldman JL, Beech J, Shields KM, Stover JA, Trepicchio WL, Larsen G, Foxwell BM, Brennan FM, Feldmann M, Pittman DD.

Mol Med. 2007 Jan-Feb;13(1-2):40-58.

26.

TCRzetadim lymphocytes define populations of circulating effector cells that migrate to inflamed tissues.

Zhang Z, Gorman CL, Vermi AC, Monaco C, Foey A, Owen S, Amjadi P, Vallance A, McClinton C, Marelli-Berg F, Isomäki P, Russell A, Dazzi F, Vyse TJ, Brennan FM, Cope AP.

Blood. 2007 May 15;109(10):4328-35. Epub 2007 Jan 25.

27.
28.

The importance of T cell interactions with macrophages in rheumatoid cytokine production.

Brennan FM, Foey AD, Feldmann M.

Curr Top Microbiol Immunol. 2006;305:177-94. Review.

PMID:
16724806
29.

Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production.

Horwood NJ, Page TH, McDaid JP, Palmer CD, Campbell J, Mahon T, Brennan FM, Webster D, Foxwell BM.

J Immunol. 2006 Mar 15;176(6):3635-41.

30.

Anti-TNF therapy: where have we got to in 2005?

Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN.

J Autoimmun. 2005;25 Suppl:26-8. Epub 2005 Nov 2. Review.

PMID:
16260118
31.

Planning your research training.

Cope AP, Brennan FM, Hill Gaston JS, Haskard DO.

Rheumatology (Oxford). 2005 Nov;44(11):1339-40. Epub 2005 Sep 13. No abstract available.

PMID:
16159949
32.

Lung-marginated monocytes modulate pulmonary microvascular injury during early endotoxemia.

O'Dea KP, Young AJ, Yamamoto H, Robotham JL, Brennan FM, Takata M.

Am J Respir Crit Care Med. 2005 Nov 1;172(9):1119-27. Epub 2005 Aug 4.

PMID:
16081546
33.

A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis.

Campbell J, Ciesielski CJ, Hunt AE, Horwood NJ, Beech JT, Hayes LA, Denys A, Feldmann M, Brennan FM, Foxwell BM.

J Immunol. 2004 Dec 1;173(11):6928-37.

34.
35.

IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis.

Lindsay JO, Sandison A, Cohen P, Brennan FM, Hodgson HJ.

Dig Dis Sci. 2004 Aug;49(7-8):1327-34.

PMID:
15387364
36.

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.

Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN.

Best Pract Res Clin Rheumatol. 2004 Feb;18(1):59-80. Review.

PMID:
15123038
38.

Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?

Feldmann M, Brennan FM, Paleolog E, Cope A, Taylor P, Williams R, Woody J, Maini RN.

Novartis Found Symp. 2004;256:53-69; discussion 69-73, 106-11, 266-9. Review.

PMID:
15027483
39.

Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.

Foey AD, Field S, Ahmed S, Jain A, Feldmann M, Brennan FM, Williams R.

Arthritis Res Ther. 2003;5(6):R317-28. Epub 2003 Sep 3.

40.

Antigen presentation by murine dendritic cells is nuclear factor-kappa B dependent both in vitro and in vivo.

Yoshimura S, Bondeson J, Brennan FM, Foxwell BM, Feldmann M.

Scand J Immunol. 2003 Aug;58(2):165-72.

41.

Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy.

Andreakos E, Smith C, Kiriakidis S, Monaco C, de Martin R, Brennan FM, Paleolog E, Feldmann M, Foxwell BM.

Arthritis Rheum. 2003 Jul;48(7):1901-12.

42.

Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.

Horwood NJ, Mahon T, McDaid JP, Campbell J, Mano H, Brennan FM, Webster D, Foxwell BM.

J Exp Med. 2003 Jun 16;197(12):1603-11.

43.
44.

Antigen-specific T-cell downregulation by human dendritic cells following blockade of NF-kappaB.

Calder VL, Bondeson J, Brennan FM, Foxwell BM, Feldmann M.

Scand J Immunol. 2003 Mar;57(3):261-70.

45.
46.

Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction.

Andreakos E, Smith C, Monaco C, Brennan FM, Foxwell BM, Feldmann M.

Blood. 2003 Feb 1;101(3):983-91. Epub 2002 Sep 19.

PMID:
12393548
47.

Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?

Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, Monaco C, Gasparini C, Sacre S, Lundberg A, Paleolog E, Horwood NJ, Brennan FM, Foxwell BM.

Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii13-8. Review.

48.

Cytokines and anti-cytokine biologicals in autoimmunity: present and future.

Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M.

Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):299-313. Review.

PMID:
12220545
49.

High-efficiency gene transfer into nontransformed cells: utility for studying gene regulation and analysis of potential therapeutic targets.

Horwood NJ, Smith C, Andreakos E, Quattrocchi E, Brennan FM, Feldmann M, Foxwell BM.

Arthritis Res. 2002;4 Suppl 3:S215-25. Epub 2002 May 9. Review.

50.

High efficiency gene transfer is an efficient way of defining therapeutic targets: a functional genomics approach.

Foxwell BM, Yoshimura S, Bondeson J, Brennan FM, Feldmann M.

Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii13-7.

Supplemental Content

Loading ...
Support Center